ACRS News and Press, Aclaris Therapeutics Inc. From 05/07/20

Projected Cash Runway into the First Quarter of 2022 Borrowed $11 Million from Term Loan Facility WAYNE, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today an...

WAYNE, Pa., March 31, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank (“SVB”) pursuant to which Aclaris has borrowed $...

The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this Read more ...

Aclaris Therapeutics, Inc. (ACRS) Q4 2019 Earnings Conference Call February 25, 2020, 05:00 PM ET Company Participants Kamil Ali-Jackson - Chief Legal Officer Neal Walker - President and CEO Frank Ruffo - CFO David Gordon - Chief Medical Officer Joe Monahan - EVP, Research an...

Penny Stocks To Watch After Coronavirus Comments This topic continues to captivate headlines: the coronavirus. A number of penny stocks have greatly benefited from speculation on “what’s next” for the virus spread. Today may have opened a bigger can of worms for investor...

Aclaris Therapeutics (NASDAQ: ACRS ): Q4 GAAP EPS of -$0.45 misses by $0.30 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor Projected Cash Runway into the Third Quarter of 2021 Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., Feb. 25, 2020 (GLOBE...

WAYNE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the fourth quarter and full year 2019, Tuesday, February 25 th , af...

AIM ImmunoTech (NYSEMKT: AIM ) +20%  on discussing the potential role of Ampligen for use against the Wuhan 2019 Novel Coronavirus. More news on: AIM ImmunoTech Inc., TransEnterix, Inc., Shopify Inc., Stocks on the move, , Read more ...

WAYNE, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the SVB Leerink 9th Annual Global Healthcare Confere...